PVI
MACK

Pura Vida Investments’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Pura Vida Investments’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-64,100
Closed -$735K – 203
2022
Q4 		$735K Buy
+64,100
New +$528K 0.04% 156

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Pura Vida Investments's MACK Position: Q1 2023 in Review

Pura Vida Investments sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2023, closing a stake of 64,100 shares — an estimated $735K sold.

Pura Vida Investments first reported a position in MACK in Q4 2022 and held it in 1 quarter. The position peaked at $735K in Q4 2022. 50 funds tracked by Wall St. Rank hold MACK as of Q1 2023.

  • Pura Vida Investments reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 64,100 Merrimack Pharmaceuticals, Inc. shares in Q1 2023, an estimated $735K.
  • Pura Vida Investments first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Merrimack Pharmaceuticals, Inc. position peaked at $735K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.